ImmunAdd at a Glance

Dedicated to enhancing human health and well-being, ImmunAdd is a biotech pharmaceutical research and development company focused on drug design and formulation development. Our team members have accumulated years of experience in medicinal chemistry, drug formulation, drug regulations, biological animal evaluation, and clinical trials. With our specialized knowledge in drug development, we aim to address the urgent needs in drug therapy and contribute to human health. Our pipeline covers vaccine adjuvant development, new formulation development, and novel drug conjugation strategies applied in vaccines, cancer, and immunotherapies.
ImmunAdd Inc. was established in 2022 as a start-up biotechnology company from National Taiwan University, founded by Professor Pi-Hui Liang and scientists with years of experience in pharmaceutical and industrial sectors.

Nov 2025 A-round fundraising

Sep 2025 A+ Contract from the Ministry of Economic Affairs (TW)

Aug 2025 Company relocation

Jul 2024 Start-up of the Year Award

2024 NSTC Outstanding Research Award

2024 Silver Medal, Tech-Transfer Award — Taipei Biotech Awards

2023 Conjugation works won the Future Tech Award

Aug 2023 Pre-A fundraising

2022 Adjuvant works won the Future Tech Award

Jun 2022 ImmunAdd founded

2021 Won the National Innovation Award of Taiwan

2021 Value-up Contract from the Ministry of Economic Affairs (TW)

2015 Began the study and synthesis of saponin adjuvants

Innovation for better health